Advan Six Inc. ASIX
We take great care to ensure that the data presented and summarized in this overview for AdvanSix Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ASIX
View all-
Black Rock Inc. New York, NY4.79MShares$109 Million0.0% of portfolio
-
Victory Capital Management Inc2.39MShares$54.6 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.95MShares$44.5 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.58MShares$36 Million0.01% of portfolio
-
Alliancebernstein L.P. New York, NY1.1MShares$25.2 Million0.01% of portfolio
-
State Street Corp Boston, MA1.08MShares$24.6 Million0.0% of portfolio
-
American Century Companies Inc Kansas City, MO740KShares$16.9 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA602KShares$13.8 Million0.0% of portfolio
-
Lsv Asset Management Chicago, IL488KShares$11.1 Million0.03% of portfolio
-
First Eagle Investment Management, LLC465KShares$10.6 Million0.03% of portfolio
Latest Institutional Activity in ASIX
Top Purchases
Top Sells
About ASIX
AdvanSix Inc. manufactures and sells polymer resins in the United States and internationally. It offers Nylon 6, a polymer resin, which is a synthetic material used to produce fibers, filaments, engineered plastics and films. The company also provides caprolactam to manufacture polymer resins; ammonium sulfate fertilizers to distributors, farm cooperatives, and retailers; and acetone that are used in the production of adhesives, paints, coatings, solvents, herbicides, and engineered plastic resins, as well as other intermediate chemicals, including phenol, alpha-methyl styrene, cyclohexanone, methyl ethyl ketoxime, acetaldehyde oxime, 2-pentanone oxime, cyclohexanol, sulfuric acid, ammonia, and carbon dioxide. It offers its products under the Aegis, Capra, Sulf-N, Nadone, Naxol, and EZ-Blox brands. The company sells its products directly, as well as through distributors. AdvanSix Inc. was incorporated in 2016 and is headquartered in Parsippany, New Jersey.
Insider Transactions at ASIX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 24
2025
|
Rachael E Ryan VP, Controller |
BUY
Grant, award, or other acquisition
|
Direct |
12,966
+37.5%
|
-
|
Mar 03
2025
|
Achilles B. Kintiroglou SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
4,000
-9.02%
|
$108,000
$27.75 P/Share
|
Feb 28
2025
|
Christopher Gramm Controller |
BUY
Grant, award, or other acquisition
|
Direct |
12,992
+11.11%
|
-
|
Feb 28
2025
|
Christopher Gramm Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
1,934
-4.45%
|
$52,218
$27.75 P/Share
|
Feb 28
2025
|
Kelly Slieter SVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,073
+20.11%
|
-
|
Feb 28
2025
|
Kelly Slieter SVP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,319
-8.46%
|
$89,613
$27.75 P/Share
|
Feb 28
2025
|
Erin N Kane Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
64,865
+10.63%
|
-
|
Feb 28
2025
|
Erin N Kane Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
22,213
-4.42%
|
$599,751
$27.75 P/Share
|
Feb 28
2025
|
Siddharth Manjeshwar SVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,415
+26.08%
|
-
|
Feb 28
2025
|
Achilles B. Kintiroglou SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
15,856
+26.33%
|
-
|
Feb 28
2025
|
Achilles B. Kintiroglou SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
4,731
-14.23%
|
$127,737
$27.75 P/Share
|
Feb 03
2025
|
Erin N Kane Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,000
-0.49%
|
$150,000
$30.42 P/Share
|
Jan 02
2025
|
Erin N Kane Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,000
-0.49%
|
$140,000
$28.5 P/Share
|
Dec 16
2024
|
Todd D. Karran Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,559
+1.91%
|
$46,770
$30.46 P/Share
|
Dec 16
2024
|
Patrick Williams Director |
BUY
Grant, award, or other acquisition
|
Direct |
430
+1.52%
|
$12,900
$30.46 P/Share
|
Dec 02
2024
|
Erin N Kane Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,000
-0.97%
|
$160,000
$32.29 P/Share
|
Nov 25
2024
|
Christopher Gramm Controller |
SELL
Open market or private sale
|
Direct |
1,951
-4.3%
|
$62,432
$32.0 P/Share
|
Nov 25
2024
|
Christopher Gramm Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
1,951
+4.12%
|
$27,314
$14.29 P/Share
|
Nov 18
2024
|
Donald P Newman Director |
BUY
Open market or private purchase
|
Direct |
5,030
+50.0%
|
$145,870
$29.64 P/Share
|
Nov 07
2024
|
Christopher Gramm Controller |
SELL
Open market or private sale
|
Direct |
505
-1.15%
|
$16,160
$32.0 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 197K shares |
---|---|
Exercise of conversion of derivative security | 10.4K shares |
Open market or private purchase | 5.03K shares |
Payment of exercise price or tax liability | 32.2K shares |
---|---|
Open market or private sale | 79.1K shares |